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Abstract
The adipokine chemerin and its receptor, chemokine-like receptor 1 (Cmklr1), are associated with insulin resistance and
nonalcoholic fatty liver disease (NAFLD), which covers a broad spectrum of liver diseases, ranging from simple steatosis to
nonalcoholic steatohepatitis (NASH). It is possible that chemerin and/or Cmklr1 exert their effects on these disorders
through inflammation, but so far the data have been controversial. To gain further insight into this matter, we studied the
effect of whole-body Cmklr1 deficiency on insulin resistance and NAFLD. In view of the primary role of macrophages in
hepatic inflammation, we also transplanted bone marrow from Cmklr1 knock-out (Cmklr1-/-) mice and wild type (WT) mice
into low-density lipoprotein receptor knock-out (Ldlr-/-) mice, a mouse model for NASH. All mice were fed a high fat, high
cholesterol diet containing 21% fat from milk butter and 0.2% cholesterol for 12 weeks. Insulin resistance was assessed by
an oral glucose tolerance test, an insulin tolerance test, and by measurement of plasma glucose and insulin levels. Liver
pathology was determined by measuring hepatic inflammation, fibrosis, lipid accumulation and the NAFLD activity score
(NAS). Whole-body Cmklr1 deficiency did not affect body weight gain or food intake. In addition, we observed no
differences between WT and Cmklr1-/- mice for hepatic inflammatory and fibrotic gene expression, immune cell infiltration,
lipid accumulation or NAS. In line with this, we detected no differences in insulin resistance. In concordance with whole-
body Cmklr1 deficiency, the absence of Cmklr1 in bone marrow-derived cells in Ldlr-/- mice did not affect their insulin
resistance or liver pathology. Our results indicate that Cmklr1 is not involved in the pathogenesis of insulin resistance or
NAFLD. Thus, we recommend that the associations reported between Cmklr1 and insulin resistance or NAFLD should be
interpreted with caution.
Citation: Gruben N, Aparicio Vergara M, Kloosterhuis NJ, van der Molen H, Stoelwinder S, et al. (2014) Chemokine-Like Receptor 1 Deficiency Does Not Affect the
Development of Insulin Resistance and Nonalcoholic Fatty Liver Disease in Mice. PLoS ONE 9(4): e96345. doi:10.1371/journal.pone.0096345
Editor: Silvia C. Sookoian, Institute of Medical Research A Lanari-IDIM, University of Buenos Aires-National Council of Scientific and Technological Research
(CONICET), Argentina
Received December 20, 2013; Accepted April 4, 2014; Published April 29, 2014
Copyright:  2014 Gruben et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was performed within the framework of CTMM, the Center for Translational Molecular Medicine (www.ctmm.nl), project PREDICCt (grant
01C-104), and supported by the Dutch Heart Foundation, the Dutch Diabetes Research Foundation (grant 2009.80.016; 2004.00.018) and the Dutch Kidney
Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Dianne J. Delsing is employed by Merck Research Laboratories. This does not alter the authors’ adherence to PLOS ONE policies on
sharing data and materials.
* E-mail: d.p.y.koonen@umcg.nl
. These authors contributed equally to this work.
Introduction
Obesity is accompanied by the development of the metabolic
syndrome, a cluster of metabolic abnormalities, which includes
low-grade inflammation, dyslipidemia and insulin resistance. Since
nonalcoholic fatty liver disease (NAFLD) is the hepatic manifes-
tation of the metabolic syndrome, its increasing prevalence follows
the increasing rates of obesity seen worldwide. As a result, NAFLD
has become one of the main causes of chronic liver disease in
Western societies [1]. NAFLD describes a broad spectrum of liver
diseases, ranging from simple steatosis (intrahepatic fat accumu-
lation) to nonalcoholic steatohepatitis (NASH), fibrosis, and
cirrhosis [2]. NASH can be distinguished from simple steatosis
by the presence of inflammation. It is unknown how NAFLD
develops or which factors provoke its progression into NASH.
Recently, an adipokine named chemerin has been implicated in
the metabolic syndrome and the progression of NAFLD.
Chemerin was first identified as a chemo-attractant protein,
attracting immune cells expressing the chemerin receptor
chemokine-like receptor 1 (Cmklr1, also known as ChemR23) [3].
This suggests that chemerin has a pro-inflammatory role.
However, studies investigating the role of Cmklr1 in inflammation
are controversial. Cmklr1 knock-out (Cmklr1-/-) mice have been
reported to be protected against central nervous system inflam-
mation [4], but they were more susceptible to lipopolysaccharide-
induced lung inflammation [5] and viral pneumonia [6]. As
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inflammation is thought to play a key role in the progression of
insulin resistance and NAFLD, chemerin and Cmklr1 may be
involved in these disorders. Indeed, in several human populations,
elevated plasma chemerin levels correlate positively with charac-
teristics of the metabolic syndrome, including inflammation,
insulin resistance, plasma lipids and body mass index [7–9]. In
addition, elevations in serum chemerin levels were found in
patients with NAFLD and NASH compared to healthy controls
[10] and have been shown to positively correlate with markers of
liver pathology, including fibrosis, portal inflammation and
NAFLD activity score (NAS) [11]. In contrast, expression of
chemerin in visceral adipose tissue in morbidly obese individuals
correlated negatively with hepatic inflammation (unpublished
data). Moreover, data on hepatic expression of chemerin and Cmklr1
in human and mouse NAFLD are inconsistent, since both reduced
and increased levels of these genes have been found [12–14].
Although these studies indicate that chemerin and its receptor may
be involved in the pathogenesis of insulin resistance and NAFLD,
a causative role remains to be established.
Thus far, only a few studies have investigated the effect of
Cmklr1 deficiency in metabolic disease and, similar to the studies
investigating inflammation, the results have been controversial. In
one study it was shown that Cmklr1 deficiency induced glucose
intolerance in mice [15], whereas another study showed no effect
of Cmklr1 deficiency on glucose intolerance [16]. In addition,
Cmklr1-/- mice were found to have reduced hepatic steatosis on a
low fat diet, but not on a high fat diet, whereas hepatic
inflammation was reduced in Cmklr1-/- mice on both diets [15].
However, differences in inflammation were not confirmed by
histological analyses and differences in body weight gain could not
be excluded as a confounding factor in this study [15]. Moreover,
despite the controversial role of Cmklr1 deficiency in inflammation,
the role of Cmklr1 in NASH has not been investigated. In the
current study, we investigated the effect of whole-body Cmklr1
deficiency on insulin resistance and NAFLD. In view of the
primary role of macrophages in NASH, we also transplanted bone
marrow from Cmklr1-/- mice and wild type (WT) mice into low-
density lipoprotein receptor knock-out (Ldlr-/-) mice. These mice
develop hepatic inflammation when fed a high fat, high cholesterol
(HFC) diet and can be regarded as a mouse model for NASH.
Materials and Methods
Ethics Statement
The University of Groningen ethics committee approved all the
animal experiments described in this paper (permit numbers
5964A and 5964E) and the animals’ discomfort was kept to a
minimum.
Mice and Bone Marrow Transplantation
Male mice deficient for Cmklr1 on a C57BL/6J background and
wild type (WT) littermates were kindly provided by MSD (Oss, the
Netherlands) and kept on a 12-hour light/12-hour dark cycle, with
ad libitum access to food and water. Starting at 3–4 months of age,
they were fed a high fat, high cholesterol (HFC) diet, containing
21% fat from milk butter and 0.2% cholesterol (Scientific Animal
Food and Engineering, Villemoisson-sur-Orge, France), for 12
weeks to induce NAFLD. To investigate the loss of Cmklr1 in bone
marrow-derived cells, female low-density lipoprotein receptor
knock-out (Ldlr-/-) mice on a C57BL/6J background (bred in-
house) were irradiated with 9.5 Gy [17] using X-Rad 320
(Precision X-ray, CT, USA) at 2–5 months of age. The next day,
these mice were transplanted with bone marrow from WT or
Cmklr1-/- mice by intravenous injection. To allow hematopoietic
cells to replenish, the mice were allowed to recover on a regular
chow diet after the transplantation procedure. After 10 weeks
recovery, chimerism was confirmed with DNA isolated from whole
blood (data not shown) and the Ldlr-/- mice were then fed a HFC
diet for 12 weeks to induce NASH.
Oral Glucose Tolerance Test and Insulin Tolerance Test
After 6 hours of fasting, the mice were subjected to an oral
glucose tolerance test (OGTT) or an insulin tolerance test (ITT).
For the OGTT, mice received a bolus of glucose (2 g/kg) and
glucose was measured with a glucose meter in blood samples taken
beforehand and at 15, 30, 60 and 120 minutes after gavage. For
the ITT, mice were injected intraperitoneally with 0.7 U/kg
insulin (WT and Cmklr1-/- mice) or 0.5 U/kg insulin (bone
marrow-transplanted Ldlr-/- mice) (Actrapid, Novo Nordisk
Canada Inc., Ontario, Canada) and blood glucose levels were
measured at the same time points.
Blood and Tissue Collection
Mice were euthanized by a heart puncture under general
anesthesia for the collection of blood and tissues. Blood was spun
at 3000 g for 10 minutes at 4uC and plasma was stored at 220uC.
Tissues were snap-frozen in liquid nitrogen or fixed in 4%
paraformaldehyde.
Hepatic Lipid Extraction and Analysis
Lipids were extracted from crushed liver samples according to
Bligh and Dyer’s method [18]. Hepatic cholesterol and triglyceride
levels were determined using commercially available kits (Roche,
Mannheim, Germany).
Plasma Measurements
Plasma cholesterol, triglycerides and free fatty acid levels were
measured with commercially available kits (cholesterol and
triglycerides: Roche; free fatty acids: DiaSys, Holzheim, Ger-
many). Chemerin and insulin were determined in plasma from
mice that had fasted for 6 hours, using commercially available
ELISA kits (chemerin: R&D systems, Abingdon, UK; insulin:
Alpco Diagnostics, Salem, NH).
Real-time PCR
RNA from homogenized liver, visceral and subcutaneous
adipose tissue (VAT and SAT) samples was isolated according to
the manufacturer’s instructions using Qiazol reagent (Qiagen,
Venlo, the Netherlands). For real-time (RT)-PCR, cDNA was
synthesized with a commercially available kit (Quantitect Reverse
Transcription, Qiagen). RT-PCR was performed using Sybr
Green Supermix (Bio-Rad, Veenendaal, the Netherlands) accord-
ing to the manufacturer’s instructions. The primer sequences are
listed in Table S1.
Histological Analysis
For histological analysis, paraffin-embedded liver, VAT and
SAT sections (4 mm) were stained with Hematoxylin-Eosin (HE).
HE-stained liver sections were scored for steatosis, lobular
inflammation and hepatocyte ballooning by a board certified
veterinary pathologist based on the Kleiner Scoring System [19].
The sum of these findings was used to determine the NAFLD
activity score (NAS). HE-stained VAT and SAT sections were
scanned using the NanoZoomer 2.0-HT slide scanner (Hama-
matsu, Herrsching am Ammersee, Germany). To estimate
adipocyte size, the number of adipocytes per mm2 were
determined on scanned sections by manually counting all the
Cmklr1 Deficiency Does Not Affect NAFLD
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adipocytes in an area of 4–5 mm2 using Aperio ImageScope (Leica
Biosystems Imaging Inc., CA, USA). Frozen-cut liver sections
(5 mm) were fixed in 4% paraformaldehyde and stained with
antibodies against the macrophage markers CD68 and CD11b.
Statistical Analysis
For statistical analysis, non-parametric t-tests were performed
using GraphPad Prism 5.0 (San Diego, USA). Data were
expressed as mean 6 SEM and the threshold for significance
was set at p,0.05.
Results
Cmklr1 Deficiency Does not Affect Body Weight or Food
Intake
As Cmklr1 is known to be necessary for adipocyte differentiation
[20] and Cmklr1-/- mice were shown to have reduced body weight
and fat mass compared to WT mice [15], we evaluated body
weight gain and food intake in mice fed a HFC diet for 12 weeks.
No differences in body weight or food intake were observed
between WT and Cmklr1-/- mice (Figs. 1A and 1B, respectively).
Figure 1. Cmklr1 deficiency does not affect body weight, food intake or plasma lipid levels. Body weight (A) and food intake (B) were
measured throughout the 12-week high fat, high cholesterol diet period. Food intake was expressed as average food intake per day. (C)
Representative pictures were taken of Hematoxylin-Eosin (HE) stained visceral and subcutaneous adipose tissue (VAT and SAT) sections. Blood
obtained by a heart puncture at the time of euthanasia was used to determine plasma triglycerides (D), plasma cholesterol (E) and plasma free fatty
acids (F). (G) Chemerin levels were determined in blood obtained from the tail vein of mice that had fasted for 6 hours at the end of the diet period.
Abbreviations: WT, wild type; Cmklr1-/-, chemokine-like receptor 1 knock-out. N = 7–8 for all experiments. Data are expressed as mean 6 SEM. * p,
0.05 vs WT.
doi:10.1371/journal.pone.0096345.g001
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Moreover, we observed no differences in the number of adipocytes
per mm2 in visceral and subcutaneous adipose tissue (VAT and
SAT) (VAT: WT, 143 cells/mm2610; Cmklr1-/-, 155 cells/
mm264, SAT: WT, 301 cells/mm2610; Cmklr1-/-, 345 cells/
mm2631), indicating that adipose tissue morphology was similar
in WT and Cmklr1-/- mice (Fig. 1C). In addition, plasma
triglycerides (Fig. 1D), cholesterol (Fig. 1E) and free fatty acid
levels (Fig. 1F) were the same in both genotypes. However, plasma
chemerin levels were significantly increased in Cmklr1-/- mice fed a
HFC diet compared to WT mice (Fig. 1G), suggesting a
compensatory upregulation of the receptor ligand. To identify
the origin of these increased plasma chemerin levels, we measured
chemerin expression in liver, visceral and subcutaneous adipose
tissue (VAT and SAT). Chemerin expression was significantly higher
in VAT and SAT, but not in the liver (Fig. S1A). As chemerin has
two other receptors, G protein coupled receptor 1 (Gpr1) and (C-C
motif) receptor-like 2 (Ccrl2) [21,22] we also measured whether the
expression of these receptors was altered. No differences were
found in the expression of these receptors in either liver tissue,
VAT or SAT (Figs. S1B and S1C).
Cmklr1 Deficiency Does not Affect the Development of
Systemic Insulin Resistance
As the chemerin-Cmklr1 system has previously been implicated
in the development of insulin resistance [15,23,24], we next
assessed the glucose tolerance and insulin sensitivity in WT and
Cmklr1-/- mice fed a HFC diet for 12 weeks. However, plasma
glucose (Fig. 2A) and insulin levels (Fig. 2B) did not differ between
the genotypes, and the mice responded similarly to an oral bolus of
glucose (Fig. 2C) and an intraperitoneal insulin injection (Fig. 2D).
This indicates that Cmklr1 deficiency does not affect the glucose
tolerance and insulin sensitivity of mice fed a HFC diet.
Cmklr1 Deficiency Does not Affect the Development of
NAFLD
To investigate whether Cmklr1 plays a role in the development
of diet-induced NAFLD, we analyzed lipid levels and gene
expression in the livers of Cmklr1-/- mice fed a HFC diet for 12
weeks. Although liver weight, expressed as a percentage of body
weight, was lower in Cmklr1-/- mice (WT, 5.70%60.21; Cmklr1-/-,
5.16%60.041, p,0.05), hepatic triglyceride content did not differ
between WT and Cmklr1-/- mice (Fig. 3A). In line with this, no
difference in hepatic cholesterol was observed between the
genotypes (Fig. 3B). The expression of genes encoding for proteins
involved in macrophage activation and infiltration (Cd68 and
Cd11b), inflammation (Mcp-1 and Tnfa) and fibrosis (aSma, Col1a1,
Timp1 and Mmp9) was similar in Cmklr1-/- mice and WT mice
(Fig. 3C). However, Il-1b gene expression was slightly, but
significantly, reduced in Cmklr1-/- mice (Fig. 3C). Furthermore,
immunostaining for CD68 and CD11b demonstrated that Cmklr1
deficiency did not affect the activation or infiltration of macro-
phages in the livers of mice fed a HFC diet (Fig. 3D). Pathological
examination of HE-stained liver sections (Fig. 3D) confirmed these
findings (Figs. S2A-C) and revealed no difference in NAS (Fig. 3E).
Hematopoietic Deletion of Cmklr1 Does not Affect the
Development of Insulin Resistance or NASH
To further investigate if Cmklr1 deficiency affects the progression
of insulin resistance and NAFLD, we transplanted bone marrow
from Cmklr1-/- mice or WT mice into Ldlr-/- mice. Ldlr-/- mice fed
a HFC diet can be regarded as a model for NASH that is
specifically driven by Kupffer cell activation and the recruitment
of macrophages [25,26]. Ldlr-/- mice transplanted with Cmklr1-/-
bone marrow cells (Ldlr-BMTCmklr1-/-) had a greater gain in body
weight than Ldlr-/- mice transplanted with WT bone marrow cells
Figure 2. Cmklr1 deficiency does not affect insulin resistance. To determine insulin resistance, glucose (A) and insulin levels (B) were
measured in mice that had fasted for 6 hours at the end of the 12-week high fat, high cholesterol diet period. In addition, an oral glucose tolerance
test (C) and an insulin tolerance test (D) were performed. Abbreviations: WT, wild type; Cmklr1-/-, chemokine-like receptor 1 knock-out. N = 7–8 for all
experiments. Data are expressed as mean 6 SEM. * p,0.05 vs WT.
doi:10.1371/journal.pone.0096345.g002
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(Ldlr-BMTWT) (Fig. 4A), and this could not be explained by
differences in food intake (Fig. S3A). In concordance, the number
of adipocytes per mm2 was lower in Ldlr-BMTCmklr1-/- mice
compared to Ldlr-BMTWT mice in both VAT (Ldlr-BMTWT,
245 cells/mm2626; Ldlr-BMTCmklr1-/-, 178 cells/mm2615;
p = 0.07) and SAT (Ldlr-BMTWT, 474 cells/mm2651; Ldlr-
BMTCmklr1-/-, 302 cells/mm2630; p,0.05), indicating that Ldlr-
BMTCmklr1-/- mice have larger adipocytes (Fig. S3B). In contrast,
Figure 3. NAFLD progression is not affected by ablation of Cmklr1. To investigate the progression of NAFLD, hepatic triglyceride (A) and
cholesterol (B) accumulation were measured in mice fed a high fat, high cholesterol diet for 12 weeks. (C) To determine the amount of inflammation
and fibrosis in the liver, the inflammatory and pro-fibrotic gene expression were measured in WT mice (white bars) and Cmklr1-/- mice (black bars). (D)
In addition, a staining for the macrophage markers CD68 and CD11b was performed on frozen-cut liver sections. (E) NAFLD Activity Score (NAS) was
determined by pathological examination of Hematoxylin-Eosin (HE) stained liver sections. Abbreviations: WT, wild type; Cmklr1-/-, chemokine-like
receptor 1 knock-out; Cd68, cluster of differentiation 68; Cd11b, alpha M integrin (Mac1); Mcp-1, monocyte chemo-attractant protein 1; Tnfa, tumor
necrosis factor a; Il1-b, interleukin 1b; aSma, a-smooth muscle actin; Col1a1, collagen type 1 alpha 1; Timp1, tissue inhibitor of metalloproteinase 1;
Mmp9, matrix metallopeptidase 9. N = 7–8 for all experiments. Data are expressed as mean 6 SEM. * p,0.05 vs WT.
doi:10.1371/journal.pone.0096345.g003
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we found no significant differences in plasma triglyceride,
cholesterol, glucose and insulin levels between the two groups of
mice (Figs. S3C-F). Moreover, hematopoietic deletion of Cmklr1
did not affect glucose tolerance (Fig. 4B) or insulin tolerance
(Fig. 4C). Whereas liver weight, expressed as a percentage of body
weight, was slightly lower in Ldlr-BMTCmklr1-/- mice compared to
Ldlr-BMTWT mice (Ldlr-BMTWT, 5.49%60.086; Ldlr-
BMTCmklr1-/-, 5.08%60.10, p,0.05), the Ldlr-BMTCmklr1-/- mice
showed a small increase in their hepatic triglyceride content and
hepatic steatosis (Fig. 4D and Fig. S3G). No differences were
observed in hepatic cholesterol accumulation (Fig. 4E). As in the
whole-body knock-out model, no differences in inflammatory gene
expression (Cd68, Mcp-1, Tnfa and Il-1b) were observed (Fig. 4F).
Examination of pro-fibrotic genes revealed a trend towards an
increase of fibrosis in Ldlr-BMTCmklr1-/- mice. However, the
differences were only significant for Col1a1 (Fig. 4F). Overall,
these data indicate that whole-body or hematopoietic ablation of
Cmklr1 does not impact on the development of systemic insulin
resistance and NAFLD in mice.
Discussion
The role of Cmklr1 in the development of insulin resistance and
NAFLD is controversial. Our data show that whole-body as well as
hematopoietic deletion of Cmklr1 in Ldlr-/- mice did not affect the
development of insulin resistance or NAFLD when the mice were
fed a HFC-diet for 12 weeks. These results raise the question
whether the alterations in serum chemerin levels and hepatic
Figure 4. Hematopoietic deletion of Cmklr1 does not affect NASH development in Ldlr-/- mice. (A) Body weight of Ldlr-BMTWT and Ldlr-
BMTCmklr1-/- mice was measured during the high fat, high cholesterol diet period of 12 weeks. Insulin resistance was assessed by an oral glucose
tolerance test (B) and an insulin tolerance test (C). NASH progression was investigated by measuring hepatic triglyceride (D) and cholesterol (E)
accumulation and by determining hepatic inflammatory and pro-fibrotic gene expression (F) in Ldlr-BMTWT mice (white bars) and Ldlr-BMTCmklr1-/-
mice (black bars). Abbreviations: Ldlr-BMTWT, low-density lipoprotein receptor knock-out mice transplanted with wild type bone marrow cells; Ldlr-
BMTCmklr1-/-, low-density lipoprotein receptor knock-out mice transplanted with chemokine-like receptor 1 knock-out bone marrow cells; Cd68, cluster
of differentiation 68; Mcp-1, monocyte chemo-attractant protein 1; Tnfa, tumor necrosis factor a; Il1-b, interleukin 1b; aSma, a-smooth muscle actin;
Col1a1, collagen type 1 alpha 1; Timp1, tissue inhibitor of metalloproteinase 1; Mmp9, matrix metallopeptidase 9. N = 5–7 for all experiments. Data are
expressed as mean 6 SEM. * p,0.05 vs WT.
doi:10.1371/journal.pone.0096345.g004
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chemerin and Cmklr1 expression found in rodent models of
NAFLD [7,12,14] are causally involved in the development and/
or progression of this disease.
In contrast to our findings, others previously reported that
Cmklr1-/- mice have reduced hepatic inflammation compared to
WT mice [15], which may be related to the reduced body weight
and fat mass found in these Cmklr1-/- mice. In line with this, the
same investigators showed that Cmklr1-/- mice have reduced
steatosis on a low fat diet. However, these differences were not
present on a high fat diet [15]. Our results confirm their latter
findings. Consistent with our results, another paper observed no
differences in body weight, fat mass and glucose tolerance between
WT and Cmklr1-/- mice at a young age. In that study, Cmklr1-/-
mice started to gain more fat mass than WT mice only from age 8
months onwards [16]. The increased body weight gain (Fig. 4A)
and adipocyte size (Fig. S3B) found in Ldlr-/- mice with a
hematopoietic deletion of Cmklr1 might therefore be an age-
induced effect. These mice were euthanized at 7–10 months of
age, whereas the whole-body knock-outs were euthanized at 6–7
months of age. These results suggest that hematopoietic cells might
be responsible for the age-induced weight gain of Cmklr1-/- mice.
In contrast to Cmklr1-/- mice, the Ldlr-BMTCmklr1-/- mice had
increased hepatic triglyceride levels (Fig. 4D), increased hepatic
steatosis (Fig. S3G) and a tendency towards an increased
expression of pro-fibrotic genes (Fig 4F). However, these
differences were small and may well be explained by the increased
body weight gain seen in these mice.
As neither whole-body Cmklr1 deficiency and hematopoietic
deletion of Cmklr1 in Ldlr-/- mice affected the development of
NAFLD, the alterations in chemerin and Cmklr1 levels found in
humans and mouse models of NAFLD may be a secondary effect
of the metabolic syndrome and NAFLD [10–12,14]. In these
disorders, many of the factors that can regulate chemerin and
Cmklr1 expression become dysregulated. First, chemerin is an
adipokine and its secretion rises with increasing adiposity. Second,
plasma TNFa levels and Tnfa expression in adipose tissue and the
liver are higher in NASH [27,28]. This cytokine has been shown
to increase chemerin expression from adipose tissue [29,30] and to
modulate chemerin activity [31]. Finally, FXR, a nuclear receptor
that regulates glucose and lipid homeostasis, induces chemerin
expression [12]. The alterations in chemerin levels found in rodent
models of NAFLD may thus be caused by increased adiposity,
increased Tnfa levels [30] or altered FXR activity in NAFLD.
Expression of Cmklr1 in hepatocytes is upregulated by adiponectin
[14]. This adipokine protects against steatosis and inflammation
and is reduced in human patients with NAFLD [32]. Thus, the
reduced expression of Cmklr1 in patients with NAFLD may be
explained by reduced adiponectin levels and it may not be causally
involved in the development of NAFLD.
A few limitations to our study must be taken into account. In
our model we studied the effects of the absence of Cmklr1, but the
other receptors that can bind chemerin, Gpr1 and Ccrl2, were still
present [21,22]. It is possible that the increased plasma chemerin
levels found in our Cmklr1-/- mice (Fig. 1G), which most likely
originate from the adipose tissue and not from the liver (Fig. S1A),
act on these receptors to compensate for the loss-of-function of
Cmklr1. So far, however, no signaling function has been described
for these receptors [33]. Moreover, we did not find any differences
in the expression of Gpr1 and Ccrl2 in liver, VAT or SAT between
WT and Cmklr1-/- mice, indicating that there is no compensatory
upregulation of these receptors due to Cmklr1 deficiency (Figs. S1B
and S1C). In addition to the other chemerin receptors, Cmklr1 has
another ligand, named resolvin E1 (RvE1). RvE1 is derived from
omega-3 polyunsaturated fatty acids and has been described to
inhibit NF-kB activity via Cmklr1 [34]. RvE1 has also been shown
to reduce fat accumulation and macrophage infiltration in the liver
and to protect against hepatocyte death [35]. This makes it even
more remarkable that Cmklr1 deficiency does not appear to affect
NAFLD development. To fully elucidate the role of Cmklr1 in
NAFLD, experiments in mice deficient for chemerin, RvE1, or
both, need to be performed.
In summary, our results show that whole-body and hemato-
poietic deletion of Cmklr1 in Ldlr-/- mice do not affect the
development of systemic insulin resistance and NAFLD in mice.
This makes it less likely that the alterations in chemerin and Cmklr1
levels found in mouse models of NAFLD [12,14] are causally
related to the development and/or progression of this disease. We
feel the associations between chemerin or Cmklr1 levels and
NAFLD should therefore be interpreted with caution.
Supporting Information
Figure S1 The expression of chemerin is increased in
adipose tissue, but not in the liver. The expression of
chemerin (A) and its receptors, Gpr1 (B) and Ccrl2 (C), was measured
in liver, visceral and subcutaneous adipose tissue of WT mice
(white bars) and Cmklr1-/- mice (black bars) fed a high fat, high
cholesterol diet for 12 weeks. Abbreviations: WT, wild type;
Cmklr1-/-, chemokine-like receptor 1 knock-out; VAT, visceral
adipose tissue; SAT, subcutaneous adipose tissue; Gpr1, G protein-
coupled receptor 1; Ccrl2, (C-C) motif receptor-like 2. N= 6-8 for
all experiments. Data are expressed as mean 6 SEM.
(TIF)
Figure S2 Steatosis, lobular inflammation and balloon-
ing scores were not affected by Cmklr1 deficiency.
Hematoxylin-Eosin (HE) stained liver sections of mice fed a high
fat, high cholesterol diet for 12 weeks were scored for steatosis (A),
lobular inflammation (B) and ballooning (C) by a certified
veterinary pathologist. Abbreviations: WT, wild type; Cmklr1-/-,
chemokine-like receptor 1 knock-out. N=8 for all experiments.
Data are expressed as mean 6 SEM.
(TIF)
Figure S3 Characteristics of bone marrow transplanted
Ldlr-/- mice. (A) Food intake was measured throughout the 12-
week high fat, high cholesterol (HFC) diet period and calculated in
grams per day. (B) Representative pictures were taken of
Hematoxylin-Eosin (HE) stained visceral and subcutaneous
adipose tissue (VAT and SAT) sections. Plasma triglycerides (C),
cholesterol (D), glucose (E) and insulin (F) levels were determined
after 12 weeks of HFC feeding. (G) Paraffin-embedded liver
sections were stained with HE for histological analysis. Abbrevi-
ations: Ldlr-BMTWT, low-density lipoprotein receptor knock-out
mice transplanted with wild type bone marrow cells; Ldlr-
BMTCmklr1-/-, low-density lipoprotein receptor knock-out mice
transplanted with chemokine-like receptor 1 knock-out bone
marrow cells. N=5–7 for all experiments. Data are expressed as
mean 6 SEM.
(TIF)
Table S1 Primer sequences.
(DOCX)
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